Description: Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a healthcare company, researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing and R&D, Healthcare Service, Medical Devices and Medical Diagnosis, Pharmaceutical Distribution and Retail, and Other business Operations. The company offers cardiovascular products, including alprostadil dried emulsion, heparin series preparation, meglumine adenosine cyclophosphate for injection, calcium dobesilate, Telmisartan, and pitavastatin calcium tablets; and deproteinized calf blood injection and quetiapine fumarate tablets for central nervous system. It also provides blood system therapeutics comprising hemocoagulase and cobamamide for injection; and metabolism and alimentary system therapeutics that include reduced glutathione series, febuxostat tablet, glimepiride, animal insulin and its formulation, recombinant human erythropoietin for injection, new compound aloe capsule, and thioctic acid injection products. In addition, the company offers anti-infection products and anti-tumor therapeutics; and API and intermediate products comprising amino acid, tranexamic acid, and clindamycin hydrochloride and heparin essence products, as well as vaccines. Further, it develops, manufactures, imports, exports, and sells medical equipment and devices, and diagnostic products; provides healthcare, hospital management, and consulting services; and researches and develops biopharmaceutical and chemical drugs, as well as engages in the retail and wholesale of medicines. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. The company was founded in 1994 and is based in Shanghai, China. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a subsidiary of Shanghai Fosun High Technology (Group) Co., Ltd.
Home Page: www.fosunpharma.com
Building A
Shanghai,
200233
China
Phone:
86 21 3398 7000
Officers
| Name | Title |
|---|---|
| Mr. Kexin Wang | Executive Co-Chairman |
| Mr. Yifang Wu | Executive Chairman |
| Mr. Deyong Wen | Joint President,CEO & Executive Director |
| Ms. Xiaohui Guan | Executive Vice Chairman |
| Mr. Shengli Li | Executive President & Chief Growth Officer |
| Ms. Rongli Feng | Executive President, Chief Human Resources Officer & GM of Human Resources Department |
| Ms. Jing Li | Executive President and CEO of Established Medicines Manufacturing & Supply Division |
| Mr. Wang Xingli M.D., Ph.D. | Executive President, Co-CEO of Innovative Medicines Division and CEO of Global R&D Center |
| Mr. Wenjie Zhang | Executive President & Co-CEO of Innovative Drug Division |
| Ms. Xiaolei Wu | VP & CFO |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 10.8108 |
|---|---|
| Trailing PE: | 16.6364 |
| Price-to-Book MRQ: | 0.7419 |
| Price-to-Sales TTM: | 0.222 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 40370 |